SCHEMBL2069294

SCHEMBL2069294

Nc1nc(-c2cccs2)ncc1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.46
ADORA2A P29274 3/20 0.46
ADORA1 P30542 3/20 0.46
ADORA2B P29275 1/20 0.46
NPC1 O15118 6/20 0.44
RAB9A P51151 5/20 0.44
ATM Q13315 2/20 0.44
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
DHFR P00374 1/20 0.40
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2069432 0.80 ADORA3 (0.46) ADORA3ADORA2AADORA1ADORA2BNPC1
SCHEMBL24786993 0.76 FOS (0.49) ADORA3ADORA2AADORA1ADORA2BKDM4E
SCHEMBL24786994 0.76 ADORA2A (0.43) ADORA3ADORA2AADORA1ADORA2BNPC1
SCHEMBL24786992 0.76 ADORA1 (0.43) ADORA3ADORA2AADORA1ADORA2BNPC1
SCHEMBL27933640 0.74 KDM4E (0.46) ADORA3ADORA2AADORA1ADORA2BNPC1
SCHEMBL2068779 0.72 ALDH1A1 (0.56) ADORA3ADORA2AADORA1ADORA2BNPC1
SCHEMBL22573374 0.71 KDM4E (0.47) ADORA3ADORA2ANPC1RAB9AATM
SCHEMBL10590818 0.70 RAB9A (0.49) NPC1RAB9AATMKDM4EALDH1A1
SCHEMBL32670806 0.70 MEN1 (0.42) ADORA2AADORA1NPC1RAB9AKDM4E
SCHEMBL27110794 0.70 KDM4E (0.50) NPC1RAB9AATMKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422271-B2 Pyrimidine compounds as tuberculosis inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-08-23 US disclosed
US-20140249137-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-04 US disclosed
US-20110053916-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249137-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS TYMS, TYMP, DPYD ADORA3 585/4885ADORA2A 984/4885ADORA1 561/4885
US-20110053916-A1 PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS TYMS, TYMP, DPYD ADORA3 585/4885ADORA2A 984/4885ADORA1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.